3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Keratosis, Actinic
22
Carcinoma, Basal Cell
10
Uterine Cervical Dysplasia
7
Melanoma
7
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Precancerous Conditions
3
Keratosis
3
Glioma
3
Glioblastoma
3
Condylomata Acuminata
3
Urinary Bladder Neoplasms
2
Squamous Intraepithelial Lesions
2
Papillomavirus Infections
2
Non-Muscle Invasive Bladder Neoplasms
2
Neoplasm Metastasis
2
Hutchinson's Melanotic Freckle
2
HIV Infections
2
Astrocytoma
2
Warts
1
Vulvar Neoplasms
1
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)
1
Virus Diseases
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sialorrhea
1
Sexually Transmitted Diseases
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
Gemcitabine
27
Fluorouracil
25
Oxaliplatin
21
Cisplatin
19
Leucovorin
17
Bevacizumab
16
Docetaxel
13
Albumin-Bound Paclitaxel
13
130-nm albumin-bound paclitaxel
13
Paclitaxel
12
Capecitabine
12
Irinotecan
11
Carboplatin
9
pembrolizumab
7
Nivolumab
7
Radiotherapy
6
Pemetrexed
6
Erlotinib Hydrochloride
6
Cyclophosphamide
6
Trastuzumab
5
Ramucirumab
5
Ipilimumab
4
Everolimus
4
Crizotinib
4
Cetuximab
4
vandetanib
3
trastuzumab deruxtecan
3
sargramostim
3
folfirinox
3
Sorafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Adenocarcinoma
×
Imiquimod
×
Clear all
NCT02234921
2018-10-11
DRibble
UbiVac
Phase 1
Completed
3 enrolled